Results 81 to 90 of about 3,096,858 (303)
KDM7A and KDM1A inhibition suppresses tumour promoting pathways in prostate cancer
Molecular Oncology, EarlyView.Treatment resistance is a major challenge for patients with advanced prostate cancer. This study examined an alternative approach to target the major prostate cancer‐promoting pathway by targeting epigenetic factors, whose levels are higher in tumours.
Jennie N Jeyapalan +16 more
wiley +1 more source
Quasi-option values for enhanced information regarding genetically modified foods [PDF]
Issues concerning the long-term environmental and health risks associated with the production of genetically modified foods remain highly topical in Australia.
Bennett, Jeffrey W. +2 more
core
BMC Musculoskeletal DisordersObjective Our meta-analysis aims to assess the efficacy of genetically modified stem cell therapy in preclinical osteoporosis models. Methods We executed a thorough literature search across PubMed, Embase, Web of Science, and the Cochrane Library ...
Miao Huang +4 more
doaj +1 more source
Molecules, 2019 In vivo tissue transparency in the visible light spectrum is beneficial for many research applications that use optical methods, whether it involves in vivo optical imaging of cells or their activity, or optical intervention to affect cells or their ...
Mikhail Inyushin +3 more
doaj +1 more source
Molecular Oncology, EarlyView.This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska +13 more
wiley +1 more source
CONSUMER ACCEPTANCE OF FOOD BIOTECHNOLOGY: WILLINGNESS TO BUY GENETICALLY MODIFIED FOOD PRODUCTS [PDF]
Biotechnology is often viewed as the defining technology for the future of food and agriculture with the potential to deliver a wide range of economic and health benefits.
Onyango, Benjamin M. +4 more
core
Molecular Oncology, EarlyView.Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura +19 more
wiley +1 more source
Post-Moratorium EU Regulation of Genetically Modified Products: Trade Concerns [PDF]
Trade in genetically modified (GM) products remains a major issue in agricultural trade policy. In particular, the European Union has sought to deny market access to GM-products.
Yeung, May T. +2 more
core
Insights on bovine genetic engineering and cloning
Pesquisa Veterinária Brasileira, 2013 Transgenic technology has become an essential tool for the development of animal biotechnologies, and animal cloning through somatic cell nuclear transfer (SCNT) enabled the generation of genetically modified animals utilizing previously modified and ...
Fabiana F. Bressan +4 more
doaj +1 more source
Loss of IGF‐1R impairs DNA‐PKcs recruitment to chromatin leading to defective end‐joining
Molecular Oncology, EarlyView.IGF‐1R promotes radioresistance by facilitating DNA‐PKcs recruitment to chromatin, enabling non‐homologous end‐joining (NHEJ) repair of double‐strand breaks. Inhibition or loss of IGF‐1R disrupts this recruitment to damage sites, driving compensatory reliance on microhomology‐mediated end‐joining (MMEJ) repair.
Matthew O. Ellis +3 more
wiley +1 more source